39 filings · most recent first
INSM 8-K Filings
Insmed Announces Positive 12Month Data From Tpip Pah Study
Insmed Incorporated Announces Voting Results From Annual Meeting
Insmed Reports Strong Q1 2026 Financial Results And Pipeline Updates
Insmed Discontinues Brensocatib Development For Hs After Phase 2B Study Fails
Insmed Announces Positive Topline Results From Phase 3B Encore Study Of
Insmed Reports Strong 2025 Financial Results And Sets 2026 Revenue Guidance
Insmed Provides Business Update With Strong 2025 Performance And Promising 2026
Insmed Discontinues Brensocatib In Crssnp And Acquires Ins1148
Insmed Announces Ec Approval Of Brinsupri For Noncystic Fibrosis Bronchiectasis
Insmed Reports Thirdquarter 2025 Financial Results And Fda Approval For
Fda Approves Insmeds Brinsupri For Noncystic Fibrosis Bronchiectasis
Insmed Reports Q2 2025 Financial Results And Business Update
Insmed Announces 650 Million Public Offering Of Common Stock
Insmed Announces Positive Topline Results From Phase 2B Study Of Tpip In Pah
Insmed Incorporated Completed Redemption Of Convertible Senior Notes
Insmed Incorporated Shareholder Approvals And Director Elections
Insmed Reports Q1 2025 Financial Results And Business Updates
Adjustment Of Convertible Senior Notes Conversion Rate
Insmed Announces Redemption Of All Outstanding Convertible Senior Notes
Insmeds Chief Commercial Officer Resigns Enters Consulting Agreement
Insmed Announces Fda Decision On Advisory Committee Meeting For Brensocatib Nda
Insmed Reports Q4 2024 Financial Results And Director Departure
Fda Grants Priority Review To Insmeds Brensocatib For Bronchiectasis
Insmed Announces Financial Results And Clinical Updates At Jp Morgan Conference
Insmed Incorporated Terminates Sales Agreement With Leerink Partners
Insmed Reports Q3 2024 Financials And Renegotiates Loan Agreement
Insmed Completed Redemption Of Convertible Senior Notes
Insmed Reports Q2 2024 Financial Results And Business Updates
Insmed Announces Additional Positive Data From Aspen Study To Be Presented At
Insmed Announces Redemption Of 225 Million Convertible Senior Notes
Insmed Retains Rights To Brensocatib As Astrazeneca Option Negotiations Fail
Insmed Hosts Commercial Webinar On Advanced Programs
Insmed Announces 500 Million Public Offering Of Common Stock
Insmed Announces Positive Topline Results From Aspen Study Of Brensocatib In
Insmed Shareholders Approve Incentive Plan Amendment And Elect Directors
Insmed Reports Firstquarter 2024 Financial Results And Clinical Trial Updates
Astrazeneca Exercises Option For Brensocatib Development In Copd And Asthma
Insmed Reports Q4 And Fullyear 2023 Financial Results And Enters New Sales
Insmed Provides Business Update And Financial Outlook For 2024